TMAO as a potential biomarker and therapeutic target for chronic kidney disease: A review

被引：40

作者：

Zixin, Ye ^{[1
,2
,3
,4
]}

Lulu, Chen ^{[5
,6
]}

Xiangchang, Zeng ^{[1
,2
,3
,4
]}

Qing, Fang ^{[5
]}

Binjie, Zheng ^{[1
,2
,3
,4
]}

Chunyang, Luo ^{[6
]}

Tai, Rao ^{[1
,2
,3
,4
]}

Dongsheng, Ouyang ^{[1
,2
,3
,4
,5
]}

机构：

[1] Cent South Univ, Xiangya Hosp, Dept Clin Pharmacol, Changsha, Peoples R China

[2] Cent South Univ, Inst Clin Pharmacol, Hunan Key Lab Pharmacogenet, Changsha, Peoples R China

[3] Minist Educ, Engn Res Ctr Appl Technol Pharmacogen, Changsha, Peoples R China

[4] Natl Clin Res Ctr Geriatr Disorders, Changsha, Peoples R China

[5] Hunan Key Lab Bioanal Complex Matrix Samples, Changsha, Peoples R China

[6] Affiliated Hosp Xiangnan Univ, Dept Clin Pharm, Chenzhou, Peoples R China

来源：

FRONTIERS IN PHARMACOLOGY | 2022年 / 13卷

关键词：

trimethylamine N-oxide; chronic kidney disease; gut microbiota; targeted TMAO drugs; mechanism; treatment; TRIMETHYLAMINE-N-OXIDE; FLAVIN-CONTAINING MONOOXYGENASE; L-CARNITINE; RENAL-INSUFFICIENCY; PROBIOTIC SUPPLEMENTATION; MICROBIAL-METABOLISM; SECONDARY PREVENTION; CONTRIBUTES; PROGRESSION; FMO3;

D O I：

10.3389/fphar.2022.929262

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The gut microbiota and its metabolites have become a hotspot of recent research. Trimethylamine N-oxide (TMAO) metabolized by the gut microbiota is closely related to many diseases such as cardiovascular disease, chronic kidney disease, type 2 diabetes, etc. Chronic kidney disease (CKD) is an important contributor to morbidity and mortality from non-communicable diseases. Recently, increasing focus has been put on the role of TMAO in the development and progress of chronic kidney disease. The level of TMAO in patients with chronic kidney disease is significantly increased, and a high level of TMAO deteriorates chronic kidney disease. This article describes the relationship between TMAO and chronic kidney disease and the research progress of drugs targeted TMAO, providing a reference for the development of anti-chronic kidney disease drugs targeted TMAO.

引用

页数：12

共 50 条

[21] Lactate: Biomarker and Potential Therapeutic Target
Okorie, Okorie Nduka
Dellinger, Phil
CRITICAL CARE CLINICS, 2011, 27 (02) : 299 - +
[22] Mineralocorticoid receptor as a therapeutic target in chronic kidney disease and hypertension
Shibata, Shigeru
Ishizawa, Kenichi
Uchida, Shunya
HYPERTENSION RESEARCH, 2017, 40 (03) : 221 - 225
[23] Adaptor protein is a new therapeutic target in chronic kidney disease
Isaka, Yoshitaka
KIDNEY INTERNATIONAL, 2017, 92 (06) : 1312 - 1314
[24] Mineralocorticoid receptor as a therapeutic target in chronic kidney disease and hypertension
Shigeru Shibata
Kenichi Ishizawa
Shunya Uchida
Hypertension Research, 2017, 40 : 221 - 225
[25] Is VEGF a new therapeutic target for hypertension in chronic kidney disease?
Kim, Yon Su
KIDNEY RESEARCH AND CLINICAL PRACTICE, 2013, 32 (02) : 49 - 51
[26] Endocan as a potential diagnostic or prognostic biomarker for chronic kidney disease
Lee, Hyun Gyu
Choi, Hoon Young
Bae, Jong-Sup
KIDNEY INTERNATIONAL, 2014, 86 (06) : 1079 - 1081
[27] Editorial: The Neurovascular Unit as a Potential Biomarker and Therapeutic Target in Cerebrovascular Disease
Nizari, Shereen
Hawkes, Cheryl A.
Hattori, Yorito
Mishra, Anusha
FRONTIERS IN AGING NEUROSCIENCE, 2022, 14
[28] Complement anaphylatoxins: Potential therapeutic target for diabetic kidney disease
Ma, Jingyuan
Yiu, Wai Han
Tang, Sydney C. W.
DIABETIC MEDICINE, 2025, 42 (02)
[29] MG53: A potential therapeutic target for kidney disease
Ke, Ben
Shen, Wen
Song, Jianling
Fang, Xiangdong
PHARMACOLOGY RESEARCH & PERSPECTIVES, 2023, 11 (01):
[30] Ferroptosis: A potential therapeutic target in autoimmune disease (Review)
Shen, Liang
Wang, Xiaohan
Zhai, Changlin
Chen, Yunqing
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2023, 26 (02)

← 1 2 3 4 5 →